ARQT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARQT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2025-03-15), Arcutis Biotherapeutics's Beta is 2.19.
The historical data trend for Arcutis Biotherapeutics's Beta can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcutis Biotherapeutics Annual Data | |||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Beta | Get a 7-Day Free Trial | - | - | 0.48 | 1.40 | 2.28 |
Arcutis Biotherapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Beta | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
1.40 | 1.80 | 1.78 | 1.98 | 2.28 |
For the Biotechnology subindustry, Arcutis Biotherapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's Beta distribution charts can be found below:
* The bar in red indicates where Arcutis Biotherapeutics's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Arcutis Biotherapeutics (NAS:ARQT) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Thank you for viewing the detailed overview of Arcutis Biotherapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.
Larry Todd Edwards | officer: Chief Commercial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Todd Franklin Watanabe | director, officer: President and CEO | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Howard G. Welgus | director | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Patrick Burnett | officer: See Remarks | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Masaru Matsuda | officer: SVP and General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Terrie Curran | director | C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Matthew Richard Moore | officer: SVP and Chief Business Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Patrick J Heron | director, 10 percent owner | 550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301 |
Frazier Life Sciences Viii, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Scott L Burrows | officer: Chief Financial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Patricia A. Turney | officer: Senior VP, Manufacturing | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
David W Osborne | officer: Chief Technical Officer | |
Kenneth A. Lock | officer: Chief Commercial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Neha Krishnamohan | director | 12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By GuruFocus News • 01-12-2025
By Marketwired • 11-06-2024
By GuruFocus News • 12-16-2024
By GuruFocus News • 11-05-2024
By Marketwired • 02-18-2025
By Marketwired • 11-04-2024
By GuruFocus News • 01-12-2025
By Marketwired • 12-06-2024
By GuruFocus News • 11-14-2024
By GuruFocus News • 11-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.